Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Alibaba Group (BABA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Alibaba Group — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Alibaba Group trades at $125.73 (market cap $308.93B). The key difference: Alibaba Group is far larger — about 10.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Alibaba Group pays a 0.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BABA | |
|---|---|---|
Market Cap | $29.60B | $308.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $189.34 |
52-Week Low | $205.48 | $94.83 |
Enterprise Value | $27.56B | $303.72B |
Volume | — | 18,069,938 |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BABA trades at $132.32, up 3.04% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong 2025 results with $996.35B revenue and $130.11B net income, though recent quarterly EPS misses raise concerns. Analyst consensus remains strongly bullish with an $195.00 price target, but multiple class action lawsuits filed in August 2026 create significant legal overhang.
BABA presents a mixed investment case with strong fundamentals and Wall Street support offset by legal risks and earnings volatility. The stock trades at reasonable valuations (P/E 19.61, P/S 2.03) with solid profitability metrics, but investors must weigh the substantial legal challenges against the company's operational strength and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
